Article

Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus.

author

Tianpei Hong

published in:  Diabetes and Metabolism
date of publication:  2016-05-10
main subject:  type 2 diabetes

Cites articles

There is nothing here

Article - wd:Q51284617

Welcome to Inventaire

the library of your friends and communities
learn more
you are offline